Neptune Technologies & Bioressources Share Price - NEPT, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information(NASDAQ:NEPT, NEPT)

Neptune Technologies & Bioressources
www.neptunebiotech.com

Neptune Technologies & Bioressources is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets.

News

26/04/12
Rodman & Renshaw starts Neptune Technologies at "Market Outperform" with $7 price target
05/10/11
Neptune Technologies receives new US patent for Krill Oil composition
28/02/11
Neptune Technologies' Acasti subsidiary to list on TSX Venture
25/11/10
Neptune Technologies shares soar 22% on positive results from cholesterol-reducing drug benchmark study
15/10/10
Neptune Technologies swings to Q2 profit, revenues rise sharply
29/09/10
Health Canada approves claims for Neptune Technologies' krill oil supplement
02/09/10
Acasti Pharma Reports Positive Impacts of CaPre Drug on Obesity and Cardiometabolic Disorders

All Neptune Technologies & Bioressources News ►

Recent Sector News

Dow seen opening higher ahead of jobless data, Facebook, Hewlett-Packard in focus

U.S. equity markets looked set to point to open higher Thursday after strong earnings from Hewlett-Packard (NYSE:HPQ), and as talks progress on Greece's debt crisis.
Dow suffers on Greece fears, Hewlett-Packard in focus

U.S. equity markets fell Wednesday afternoon on concerns that Greece could exit the euro as the region’s gather for an informal meeting.
Dow points lower ahead of eurozone meeting, Facebook, Dell in focus

U.S. equity markets looked set to open lower Wednesday morning ahead of a meeting of European Union leaders amid continued worries over the eurozone debt crisis.
Q1 gold demand underpinned by China, Central Banks and ETFs

Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up

Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
Facebook boosts public offering by 25%

Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.